The Pharmacy Times® Oncology Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to oncology pharmacists.
January 27th 2025
Axatilimab-csfr is a colony-stimulating factor-1 receptor (CSFR1) blocking monoclonal antibody indicated for cGVHD after 2 or more lines of prior therapy in adults and pediatric patients that weigh at least 40 kg.